Compare Ginkgo Bioworks Holdings Inc (DNA) vs RLX Technology Inc (RLX) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.

DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.

RLX trades at $1.73, unchanged on the day, and has recently set new 52-week lows. The technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported $3.62B in 2025 revenue and $921.87M net income, though recent quarters show earnings misses against expectations. International expansion, now 70% of revenue, drives growth, but margin compression is a concern. Analyst coverage is limited, with a single hold rating indicating caution.

The outlook is mixed; strong international growth and a discounted valuation (P/E 15.46, P/B 0.91) offer potential upside, but persistent earnings misses, bearish technicals, and regulatory risks in the e-vapor industry pose significant headwinds. Investor sentiment remains neutral to cautious amid recent price weakness.